Mevion to Bring MEVION S250-FIT™ Proton Therapy System to Multidisciplinary Care Setting

The advanced compact proton therapy platform will expand access for pediatric and adult cancer patients at Dana-Farber Cancer Institute

BOSTON--(BUSINESS WIRE)--Mevion Medical Systems, a leader in compact proton therapy solutions, today announced that Dana-Farber Cancer Institute will install the MEVION S250-FIT Proton Therapy System™ at its Longwood Medical Area campus. The installation will integrate proton therapy directly into Dana-Farber's multidisciplinary care environment, including pediatric care delivered through the Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

“Proton therapy is a critical tool in modern radiation oncology and cancer care, delivering the precision needed to eradicate malignant tumors while sparing surrounding healthy tissues and minimizing side effects,” said Dr. Peter F. Orio, Chair of the Department of Radiation Oncology at Dana-Farber. “We are eager to make state-of-the-art proton therapy available to our pediatric and adult patients, bringing the right treatment to the right patient, exactly when and where it is needed most.”

Proton therapy deposits radiation directly into the tumor with minimal exit dose, significantly reducing exposure to surrounding tissues. It is recognized in national guidelines for select cancers; it is especially valuable for pediatric patients and for tumors near critical organs.

“By adding proton therapy to our Longwood campus, we are expanding the range of advanced treatments we can offer in one location,” said Gerard Walsh, Vice President of Radiation Oncology at Dana-Farber. “This investment reflects our commitment to ensuring patients have access to the most effective technologies available.”

The MEVION S250-FIT is the first proton therapy system designed to fit within an existing linear accelerator vault, reducing the space, cost, and time needed to bring proton therapy online. The platform includes Mevion’s HYPERSCAN^® pencil-beam scanning for Intensity-Modulated Proton Therapy (IMPT) and is designed to deliver DirectARC™ proton arc therapy, aligning with modern radiotherapy workflows. Central to this approach is Marie^®, Leo Cancer Care’s upright patient positioning and imaging solution, which enables treatment delivery by rotating the patient rather than a large machine. This fundamentally changes how radiotherapy systems can be designed, removing the need for large rotating gantries and enabling faster and more compact installations.

“Dana-Farber’s decision to integrate proton therapy into its Longwood campus reflects a clear vision for innovation and patient access,” said Tina Yu, PhD, Chief Executive Officer of Mevion Medical Systems. “Our FIT system was created to bring the full benefits of proton therapy into leading hospitals without the barriers of traditional large facilities.”

About Mevion Medical Systems:
Mevion Medical Systems is a leading provider of compact proton therapy systems for cancer care. Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion pioneered the single-room platform and continues to further the science and application of proton therapy. Since 2013, Mevion compact proton therapy single-room systems have been used by leading cancer centers for treating patients. Mevion’s series of products, including the flagship MEVION S250i^® and MEVION S250-FIT™ with HYPERSCAN^® pencil beam scanning, represent the world’s most compact proton therapy systems that eliminate the obstacles of size, complexity, and cost. Mevion is headquartered in Littleton, Massachusetts with a presence in Europe and Asia. For more information, please visit www.mevion.com